<DOC>
	<DOCNO>NCT01431391</DOCNO>
	<brief_summary>The main purpose study determine whether ADT start sipuleucel-T lead well immune system response . This study also evaluate safety sipuleucel-T treatment , immune system response time , characteristic sipuleucel-T , change prostate specific antigen ( PSA ) value time .</brief_summary>
	<brief_title>Sequencing Sipuleucel-T ADT Men With Non-metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically document prostate cancer Prior primary therapy prostate cancer Rising prostate specific antigen ( PSA ) PSA double time ( PSADT ) ≤ 12 month Nonmetastatic disease ECOG performance status ≤ 1 Testosterone ≥ 200 ng/dL ≤ 28 day registration Adequate hematologic , renal , liver function Must live permanent residence within comfortable drive distance ( roundtrip within one day ) clinical research site Requires systemic ongoing immunosuppressive therapy History allergic reaction attribute compound similar chemical biologic composition sipuleucelT GMCSF Prior sipuleucelT therapy Prior ADT therapy ≤ 6 month prior registration 6 month duration total Diseasefree treatment 10 year stage III/IV malignancies 5 year stage I/II malignancies Prior experimental immunotherapy within 1 year Received denosumab XRT ≤ 6 month prior registration Received chemotherapy GMCSF ≤ 90 day prior registration Received following medication intervention ≤ 28 day prior registration major surgery require general anesthesia systemic immunosuppressive therapy prescription treatment prostate cancer Active infection within 1 week registration Likely receive XRT surgery prostate cancer study period</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>immune therapy</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>therapeutic vaccine</keyword>
	<keyword>therapeutic cancer vaccine</keyword>
	<keyword>vaccine</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>PSA</keyword>
	<keyword>androgen deprivation therapy</keyword>
	<keyword>Prostatic Neoplasms</keyword>
	<keyword>Genital Neoplasms , Male</keyword>
	<keyword>Urogenital Neoplasms</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Prostatic Diseases</keyword>
	<keyword>Androgens</keyword>
	<keyword>Hormones</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Neoplasms , Glandular Epithelial</keyword>
	<keyword>immunology</keyword>
	<keyword>hormone therapy</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>LHRH</keyword>
</DOC>